Adlai Nortye Ltd. American Depositary Shares (ANL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has a cash flow conversion efficiency ratio of -0.266x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($53.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adlai Nortye Ltd. American Depositary Sh (ANL) net asset quality to measure how much of total assets are equity-financed.
Adlai Nortye Ltd. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Adlai Nortye Ltd. American Depositary Sh long-term investment allocation to see how much of total assets are deployed in long-term investments.
Adlai Nortye Ltd. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
Clevo Co
TW:2362
|
-0.065x |
|
Jilin Forest
SHG:600189
|
0.056x |
|
Better Collective
ST:BETCO
|
0.030x |
|
Shanghai Chuangli Group Co Ltd
SHG:603012
|
0.010x |
|
Anteris Technologies Global Corp. Common Stock
NASDAQ:AVR
|
-0.103x |
|
Replimune Group Inc
NASDAQ:REPL
|
-0.313x |
|
CSBC Corp Taiwan
TW:2208
|
-0.623x |
Annual Cash Flow Conversion Efficiency for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Adlai Nortye Ltd. American Depositary Sh.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-8.32 Million | $-33.54 Million | 4.030x | +298.21% |
| 2024-12-31 | $25.48 Million | $-51.82 Million | -2.033x | -169.35% |
| 2023-12-31 | $75.05 Million | $-56.65 Million | -0.755x | -521.42% |
| 2022-12-31 | $-241.29 Million | $-43.22 Million | 0.179x | +994.79% |
| 2021-12-31 | $-185.43 Million | $-3.03 Million | 0.016x | -93.78% |
| 2020-12-31 | $-131.56 Million | $-34.59 Million | 0.263x | +22.25% |
| 2019-12-31 | $-69.38 Million | $-14.92 Million | 0.215x | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more